Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

2.

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M.

PLoS One. 2016 May 12;11(5):e0155165. doi: 10.1371/journal.pone.0155165. eCollection 2016.

3.

Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.

Pont MJ, van der Lee DI, van der Meijden ED, van Bergen CA, Kester MG, Honders MW, Vermaat M, Eefting M, Marijt EW, Kielbasa SM, Hoen PA, Falkenburg JH, Griffioen M.

Clin Cancer Res. 2016 Aug 15;22(16):4185-96. doi: 10.1158/1078-0432.CCR-15-2307. Epub 2016 Mar 10.

4.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Pont MJ, Hobo W, Honders MW, van Luxemburg-Heijs SA, Kester MG, van Oeveren-Rietdijk AM, Schaap N, de Boer HC, van Bergen CA, Dolstra H, Falkenburg JH, Griffioen M.

Haematologica. 2015 Oct;100(10):e419-22. doi: 10.3324/haematol.2015.125021. Epub 2015 Jun 11. No abstract available.

5.

Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies.

Kremer AN, van der Meijden ED, Honders MW, Pont MJ, Goeman JJ, Falkenburg JH, Griffioen M.

Biol Blood Marrow Transplant. 2014 May;20(5):742-7. doi: 10.1016/j.bbmt.2014.02.005. Epub 2014 Feb 14.

6.

Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?

van Bergen CA, Verdegaal EM, Honders MW, Hoogstraten C, Steijn-van Tol AQ, de Quartel L, de Jong J, Meyering M, Falkenburg JH, Griffioen M, Osanto S.

PLoS One. 2014 Jan 15;9(1):e85198. doi: 10.1371/journal.pone.0085198. eCollection 2014.

7.

Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

Kremer AN, van der Griendt JC, van der Meijden ED, Honders MW, Ayoglu B, Schwenk JM, Nilsson P, Falkenburg JH, Griffioen M.

Haematologica. 2014 Feb;99(2):365-9. doi: 10.3324/haematol.2013.086652. Epub 2013 Oct 4.

8.

Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.

Kremer AN, van der Meijden ED, Honders MW, Goeman JJ, Wiertz EJ, Falkenburg JH, Griffioen M.

Blood. 2012 Oct 18;120(16):3246-55. doi: 10.1182/blood-2011-12-399311. Epub 2012 Aug 13.

9.

Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.

Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1196-204. doi: 10.3324/haematol.2011.049478. Epub 2012 Mar 14.

10.

Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.

Griffioen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA, von dem Borne PA, van Rood JJ, Willemze R, Falkenburg JH.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42. doi: 10.1073/pnas.0712250105. Epub 2008 Mar 3.

11.

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer.

Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH.

Blood. 2006 Jun 15;107(12):4954-60. Epub 2006 Feb 23.

12.

Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.

Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM.

Leuk Res. 2003 May;27(5):445-53.

PMID:
12620296
13.

Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.

Veuger MJ, Honders MW, Willemze R, Barge RM.

Eur J Haematol. 2002 Sep;69(3):171-8.

PMID:
12406011
14.

Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.

Veuger MJ, Heemskerk MH, Honders MW, Willemze R, Barge RM.

Blood. 2002 Feb 15;99(4):1373-80.

15.
16.

High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.

Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM.

Blood. 2000 Aug 15;96(4):1517-24.

19.

Cloning of the Dck gene encoding rat deoxycytidine kinase.

Stegmann AP, Honders MW, Willemze R, Landegent JE.

Gene. 1994 Dec 15;150(2):351-4.

PMID:
7821805
20.

Assignment of the human deoxycytidine kinase (DCK) gene to chromosome 4 band q13.3-q21.1.

Stegmann AP, Honders MW, Bolk MW, Wessels J, Willemze R, Landegent JE.

Genomics. 1993 Aug;17(2):528-9. No abstract available.

PMID:
8406512

Supplemental Content

Loading ...
Support Center